Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma : Tolerability and efficacy studyvthe israeli experience

International Journal of Gynecological Cancer

Volumn 23, Issue 3, 2013, Pages 475-480

  Safra, Tamar ^a   Berman, Tara ^b   Yachnin, Adelya ^c   Bruchim, Ilan ^d   Meirovitz, Mihai ^e   Barak, Frida ^f   Atlas, Ilan ^g   Levy, Tally ^a   Rosengarten, Ora Solange ^h  

^a TEL AVIV UNIVERSITY   (Israel)

^b St Luke's Roosevelt Medical Center   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d MEIR MEDICAL CENTER   (Israel)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^g BAR ILAN UNIVERSITY   (Israel)

^h HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Ovarian cancer; Platinum sensitivity; Response; Topotecan regimen; Toxicity

Indexed keywords

TOPOTECAN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PRIMARY PERITONEUM CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISRAEL; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 84876236047     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182866944     Document Type: Article

References (25)

1. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009;472:413-437.
2. Guarneri V, Piacentini F, Barbieri E, et al. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol. 2010;117:152-158.
3. Salzberg M, Thurlimann B, Bonnefois H, et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology. 2005;68:293-298.
4. McGuire WP, Blessing JA, Bookman MA, et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 2000;18:1062-1067.
5. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389-393.
6. Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry. 1989;28:4629-4638.
7. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989;49:5077-5082.
8. Clements MK, Jones CB, Cumming M, et al. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol. 1999;44:411-416.
9. O'Leary JJ, Shapiro RL, Ren CJ, et al. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res. 1999;5:181-187.
10. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol. 1996;14:3056-3061.
11. Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996;14:1552-1557.
12. ten Bokkel-Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183-2193.
13. Hoskins P, Eisenhauer E, Beare S, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1998;16:2233-2237.
14. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998;16:3345-3352.
15. Morris R, Alvarez RD, Andrews S, et al. Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. Gynecol Oncol. 2008;109:346-352.
16. Bolis G, Scarfone G, Tateo S, et al. Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel. Gynecol Oncol. 2001;80:13-15.
17. Sehouli J, Stengel D, Harter P, et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: A randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2011;29:242-248.
18. Safra T, Menczer J, Bernstein R, et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol. 2007;105:205-210.
19. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol. 2003;21:187s-193s.
20. Abushahin F, Singh DK, Lurain JR, et al. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol. 2008;108:53-57.
21. Bhoola SM, Coleman RL, Herzog T, et al. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol. 2004;95:564-569.
22. O'Malley DM, Azodi M, Makkenchery A, et al. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2005;98:242-248.
23. Herzog TJ, Sill MW, Walker JL, et al. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol. 2011;120:454-458.
24. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322.
25. Hyman DM, Zhou Q, Arnold AG, et al. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol. 2011;123:196-199.